直乙交界处肠癌患者KRAS和BRAF基因突变138例分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2599 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To identify the mutation rate and mutation feature of KRAS and BRAF gene in patients with rectosigmoid carcinoma, to analyse the association between KRAS/BRAF mutations and patients’ clinicopathological characteristics, and discuss the clinical significance of KRAS/BRAF mutations. Methods: 138 patients with rectosigmoid carcinoma were collected. DNA sequencing was used to detect mutations in KRAS (codons12, 13 of exon2 and codons 61 of exon3) and BRAF (exon15). Statistically analyzing the relationships between gene mutations and clinicopathological characteristic. Results: In 138 cases, the mutation rate of KRAS and BRAF was 34.05% (47/138) and 5.07% (7/138). 9 mutation types were found in KRAS, including a new mutation type. BRAF mutation was all belong to V600E mutation. In patients with rectosigmoid carcinoma, KRAS mutation rate was higher in male (P=0.041), distant metastasis (P=0.002) and high clinical stages (P=0.047). BRAF mutation rate was higher in multiple (P=0.003) and poorly differentiate (P=0.001) carcinoma. No significant associations were observed between KRAS/BRAF mutations and age, tumor size, pathomorphism, pathological type, depth of invasion, lymph node metastasis, vessel infiltration and nervous infiltration (P>0.05). Conclusion: Rectosigmoid carcinoma is unique. KRAS mutation rate is higher in male, distant metastasis and high clinical stages carcinoma. BRAF mutation rate is higher in multiple and poorly differentiate carcinoma.KRAS and BRAF mutations are variant in different location of colorectal cancer.

Key words： rectosigmoid intestinal neoplasms clinicopathological characteristic KRAS gene BRAF gene

Received: 22 December 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Fan1
	CAI Yefeng1
	JIN Langping1
	ZHANG Xiaohua2
	QU Jinmiao2.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I9/646

[1] 王宁, 孙婷婷, 郑荣寿, 等. 中国2009年结直肠癌发病和死亡资料分析[J]. 中国肿瘤, 2013, 22(7): 515-520.
[2] Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2007, 26(10): 1626-1634.
[3] 吴伟, 孙文勇. BRAF基因突变与结直肠癌的研究进展[J].实用医学杂志, 2011, 27(5): 903-905.
[4] Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer[J]. Lancet Oncol, 2005, 6(5): 322-327.
[5] 高静, 孙志伟, 李艳艳, 等. 中国结直肠癌患者966例中KRAS和BRAF基因突变分析[J]. 中华病理学杂志, 2012, 41(9): 579-583.
[6] 朱晓丽, 蔡旭, 张玲, 等. 中国结直肠癌患者中KRAS与BRAF基因突变特征及其临床病理相关性[J]. 中华病理学杂志, 2012, 41(9): 584-589.
[7] 沈永奇, 冯献斌. 结直肠癌K-ras基因的研究进展[J]. 医学综述, 2011, 17(13): 1954-1957.
[8] Schmidt CR, Washington MK, Gi YJ, et al. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase[J]. Am J Surg, 2003, 186 (5): 426-430.
[9] Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients[J]. Ann Oncol, 2008, 19(4): 717-723.
[10] Normanno N, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC[J]. NatRev Clin Oncol, 2009, 6(9): 519-527.
[11] Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies[J]. Cancer Res, 2007, 67(6): 2643-2648.
[12] DiNicolantonio F, Martini M, Molinari F, et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer[J]. J Clin Oncol, 2008,26(35): 5705-12.
[13] Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008,26(35): 5705-5712.
[14] 沈胤晨, 王建飞, 杨红鹰. 结直肠癌患者BRAF基因突变检测及其临床意义[J]. 中华检验医学杂志, 2012, 35(11): 993-999.
[15] 曹祥龙, 汪欣. 结直肠癌KRAS和BRAF基因突变的实验研究与临床意义[J]. 中国医刊, 2013, 48(7): 23-26.
[16] Bagla N, Schofield JB. Rectosigmoid tumours: should we continue sitting on the fence?[J]. Colorectal Dis, 2007, 9(7): 606-608.
[17] 陶雅军, 段世政, 张明, 等. 649例大肠癌临床病理特征分析[J]. 实用肿瘤学杂志, 2006, 20(6): 489-490.
[18] 赖少清, 鞠凤环, 王贵齐, 等. 2004~2008年704例大肠癌临床流行特征[J]. 中国肿瘤, 2010, 19(2): 111-113.
[19] Mukai M, Kishima K, Yamazaki M, et al. Stage II/III cancer of the rectosigmoid junction: An independent tumor type? [J]. Oncol Rep, 2011, 26(3): 737-741.
[20] 尹德奎, 张红春, 马丽霞, 等. X线、内镜及超声联合应用在直乙肠交界处结肠癌诊断及分期中的价值[J]. 中国临床医学影像杂志, 2007, 18(4): 296-298.